# A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

> **NCT01903993** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 287 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT01903993
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-06
- **Primary completion:** 2015-11-19
- **Final completion:** 2018-09-06
- **Target enrollment:** 287 (ACTUAL)
- **Last updated:** 2019-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01903993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01903993, "A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01903993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*